glycopyrronium cloths

Phase 2Small molecule

UUniversity of Utah

glycopyrronium cloths is one of 16 small molecule programs targeting Hyperhidrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperhidrosisActive, not recruiting

HyperhidrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Hyperhidrosis

#DrugCompanyPhaseTrials

Oxytrol

WWim Janssens

Approved

6 2

Botulinum Toxin a

GSK

Approved

1 3

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 4

GSK1358820

GSK

Phase 3

1 5

Botox

RRevance Therapeutics, Inc.

Phase 2

9 6

Meditoxin

MMedy-Tox

Phase 3

1 7

Botox

AbbVie

Phase 2

1 8

Sofdra

BBotanix Pharmaceuticals

Phase 3

4 9

Glycopyrronium Bromide

Novartis

Phase 2

1 10

Incruse Ellipta

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperhidrosis1 trial

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Completed·UUniversity of Utah·Phase 2·NCT04924036·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for glycopyrronium cloths. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — glycopyrronium cloths compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for glycopyrronium cloths. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Utah

glycopyrronium cloths

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperhidrosis1 trial

References

Drug Info

Quick Facts

Related News